{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-031059","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.140593+00:00","generated_at":"2026-05-30T15:41:10.793725+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity regains Nasdaq minimum bid price compliance after 20-day period","bullets":["Received Nasdaq notice on Oct 9, 2024 confirming compliance with Listing Rule 5550(a)(2).","Stock closing bid price was $1.00 or greater for 20 consecutive days from Sept 11 to Oct 9, 2024.","Non-compliance was first notified on June 18, 2024; this matter is now closed.","CEO Thomas Jensen stated focus remains on stenoparib Phase 2 trial in advanced ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-031059","json":"https://secwatch.observer/filing/0001437749-24-031059.json","markdown":"https://secwatch.observer/filing/0001437749-24-031059.md","text":"https://secwatch.observer/filing/0001437749-24-031059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924031059/0001437749-24-031059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924031059/allr20241010_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:41:10.793725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}